MyFinsight
Home
Blog
About
Accounts receivable
-$34,851K
Proceeds from exercise of
common stock options...
$5,785K
(211.86%↑ Y/Y)
Stock-based compensation
$9,062K
(-58.17%↓ Y/Y)
Accrued expenses
$4,045K
(-12.58%↓ Y/Y)
Other long-term
assets
-$1,031K
(-439.79%↓ Y/Y)
Depreciation
$463K
(-56.32%↓ Y/Y)
Net cash provided by
(used in) operating...
$12,484K
(130.57%↑ Y/Y)
Net cash provided by
financing activities
$2,240K
(48.54%↑ Y/Y)
Canceled cashflow
$36,968K
Canceled cashflow
$3,545K
Net decrease in
cash, cash...
-$24,060K
(93.64%↑ Y/Y)
Canceled cashflow
$14,724K
Maturities of short-term
investments
$106,260K
(-15.66%↓ Y/Y)
Net loss
-$21,972K
(61.70%↑ Y/Y)
Deferred revenue
-$10,118K
Accretion of discounts on
investments, net
$2,886K
(-69.39%↓ Y/Y)
Prepaid expenses and
other current assets
$1,612K
(53.67%↑ Y/Y)
Accounts payable
-$342K
(34.73%↑ Y/Y)
Operating lease
right-of-use assets and...
$38K
(245.45%↑ Y/Y)
something is missing
-$3,545K
Net cash used in
investing activities
-$38,784K
(88.55%↑ Y/Y)
Canceled cashflow
$106,260K
Purchases of short-term
investments
$144,842K
(-68.78%↓ Y/Y)
Purchases of property and
equipment
$202K
(-76.07%↓ Y/Y)
Back
Back
Cash Flow
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)
source: myfinsight.com